Analytical Data
-
基因名
TNFRSF17
- Application
-
别名
TNFRSF17；BCM；BCMA；Tumor necrosis factor receptor superfamily member 17
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q02223
-
表达区间
5-54aa
-
氨基酸序列
AGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNA
-
分子量
5 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TNFRSF17, also known as BCMA (B-cell maturation antigen), is a member of the tumor necrosis factor receptor superfamily that plays a crucial role in B cell development and survival. It has gained significant attention in recent years due to its pivotal role in multiple myeloma and other B-cell malignancies. BCMA is predominantly expressed on terminally differentiated plasma cells and has been implicated in promoting cell proliferation, survival, and immune regulation. The development of BCMA-targeted therapies, including monoclonal antibodies and CAR-T cell therapies, has revolutionized the treatment landscape for multiple myeloma, leading to remarkable clinical outcomes. To facilitate these therapeutic approaches, the production and characterization of recombinant TNFRSF17 proteins are vital for understanding the receptor's structure, function, and interaction with ligands, as well as for identifying potential biomarkers for patient stratification. Furthermore, these recombinant proteins can serve as tools for drug development, enabling the screening of new therapeutic candidates and the exploration of mechanistic insights in BCMA-mediated signaling pathways. Thus, the research on TNFRSF17 recombinant proteins is essential for advancing both fundamental science and clinical applications in the context of B-cell-related diseases.
